Congressional language stipulates the FY24 PRCRP must not address research in melanoma, glioblastoma, or cancers originating in the breast, pancreas, prostate, ovary, kidney, or lung. In addition, FY24 PRCRP funds must not be used to study rare cancers except for subtypes of the FY24 PRCRP topic areas that are rare by definition. Applicants are directed to apply to the individual CDMRP cancer programs in those disease areas. The FY24 PRCRP Topic Areas are listed below.

• Bladder cancer
• Blood cancers
• Brain cancer (except glioblastoma)
• Colorectal cancer
• Endometrial cancer
• Esophageal cancer
• Germ cell cancers
• Liver cancer
• Lymphoma
• Mesothelioma
• Metastatic cancers¹
• Myeloma
• Neuroblastoma
• Pediatric, adolescent, and young adult cancers²
• Pediatric brain tumors
• Sarcoma
• Stomach cancer
• Thyroid cancer

¹ Metastatic cancer is cancer that has spread from its original location to another place in the body, representing what are known as stage III and stage IV cancer diagnoses. While recent research has revealed that there is a genetic basis for susceptibility or resistance to metastasis, more research is needed to develop a comprehensive understanding of this complex process.

² The definition of adolescents and young adults is derived from the National Cancer Institute(https://www.cancer.gov/types/aya).Research should be targeted toward pediatric (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).